Alterations in the levels of PTEN, microRNAs, and PTENP1 are a new frontier in cancer therapeutics with the potential to reverse the cancer phenotype by positively manipulating the PTEN–microRNA–PTENP1 axis in favour of a precancerous cellular phenotype. The gene discussed is PTENP1; the disease is cancer.